Publications by authors named "Edel Falla"

Claim this Profile
T
The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?
Sian Tanner, Rebecca Coady, Ana Lisica, Edel Falla, Anke van Engen

J Mark Access Health Policy· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calibration of the IQVIA Core Diabetes Model to the stroke outcomes from the SUSTAIN 6 cardiovascular outcomes trial of once-weekly semaglutide.
Sasha Berry, Barrie Chubb, Annabel Acs, Edel Falla, Akanksha Verma

J Med Econ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.
Juan-Enrique Schwarze, Christos Venetis, Silvia Iniesta, Edel Falla, Vasily Lukyanov

Best Pract Res Clin Obstet Gynaecol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
Klaus Bühler, Claudia Roeder, Juan-Enrique Schwarze, Monica Lispi, Arthur Allignol, Edel Falla

Best Pract Res Clin Obstet Gynaecol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
Daniela Zinzi, Ioanna Vlachaki, Edel Falla, Theo Mantopoulos, Dilip Nathwani

Eur J Health Econ· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK.
Ioanna Vlachaki, Daniela Zinzi, Edel Falla, Theo Mantopoulos, Holly Guy

Eur J Health Econ· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
Rory J McCrimmon, Edel Falla, Jo Zhou Sha, Abdul Jabbar Omar Alsaleh, Elisheva Lew

Diabetes Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis.
Ioanna Vlachaki, Matteo Vacchelli, Daniela Zinzi, Edel Falla, Yilin Jiang

BMC Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany.
Weiguang Xue, Adam Lloyd, Edel Falla, Claudia Roeder, Rudiger Papsch

Int J Womens Health· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis